These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 543764)

  • 1. Evidence for, and localization of, a unitary dopamine receptor composed of cooperatively linked subunit binding sites in rat striatum.
    Leysen JE; Gommeren W; Laduron PM
    Arch Int Pharmacodyn Ther; 1979 Dec; 242(2):312-4. PubMed ID: 543764
    [No Abstract]   [Full Text] [Related]  

  • 2. Unitary dopaminergic receptor composed of cooperatively linked agonist and antagonist sub-unit binding sites.
    Leysen JE
    Commun Psychopharmacol; 1979; 3(6):397-410. PubMed ID: 546588
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopamine antagonist binding increases in two behaviorally distinct striatal denervation syndromes.
    Thal L; Mishra RK; Gardner EL; Horowitz SG; Varmuza S; Makman MH
    Brain Res; 1979 Jul; 170(2):381-6. PubMed ID: 572733
    [No Abstract]   [Full Text] [Related]  

  • 4. Localization of opiate receptors and enkephalins in the rat striatum in relationship with the nigrostriatal dopaminergic system: lesion studies.
    Pollard H; Llorens C; Schwartz JC; Gros C; Dray F
    Brain Res; 1978 Aug; 151(2):392-8. PubMed ID: 209865
    [No Abstract]   [Full Text] [Related]  

  • 5. Dopaminergic receptor activity in substantia nigra in the mechanisms of autoregulation of striatal dopamine release.
    Groppetti A; Parenti M; Cattabeni F; Maggi A; De Angelis L; Monduzzi M; Racagni G
    Adv Biochem Psychopharmacol; 1978; 19():363-71. PubMed ID: 696464
    [No Abstract]   [Full Text] [Related]  

  • 6. Apomorphine-induced inhibition of striatal dopamine release: role of dopaminergic receptors in substantia nigra.
    Maggi A; Bruno F; Cattabeni F; Groppetti A; Parenti M; Racagni G
    Brain Res; 1978 Apr; 145(1):180-4. PubMed ID: 205324
    [No Abstract]   [Full Text] [Related]  

  • 7. Localization of dopamine receptors in rat brain.
    Reisine TD; Nagy JI; Fibiger HC; Yamamura HI
    Brain Res; 1979 Jun; 169(1):209-14. PubMed ID: 455093
    [No Abstract]   [Full Text] [Related]  

  • 8. Demonstration of a complex subunit composition of a unitary dopamine receptor: effects of lesions and proteolytic enzymes on stereospecific binding.
    Leysen JE; Gommeren W; Van Gompel P
    Adv Biochem Psychopharmacol; 1983; 36():147-62. PubMed ID: 6858752
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of nigrostriatal 6-hydroxydopamine lesions on dopamine D2 receptor mRNA and opioid systems.
    Mansour A; Meador-Woodruff JH; Camp DM; Robinson TE; Bunzow J; Van Tol H; Civelli O; Akil H; Watson SJ
    Prog Clin Biol Res; 1990; 328():227-30. PubMed ID: 2106148
    [No Abstract]   [Full Text] [Related]  

  • 10. Supersensitivity of the cholinergic response to apomorphine in the striatum following denervation or disuse supersensitivity of dopaminergic receptors in the rat.
    Consolo S; Ladinsky H; Samanin R; Bianchi S; Ghezzi D
    Brain Res; 1978 Oct; 155(1):45-54. PubMed ID: 210895
    [No Abstract]   [Full Text] [Related]  

  • 11. The effects of dopaminergic denervation on Na+-K+ ATPase activity and 3H-ouabain binding in rat corpus striatum.
    Bjur RA; Westfall DP
    Proc West Pharmacol Soc; 1984; 27():35-8. PubMed ID: 6093132
    [No Abstract]   [Full Text] [Related]  

  • 12. Basal ganglia dopamine depletion does not alter D1 dopamine receptor binding properties.
    Trugman JM; Pronsky CJ; Wooten GF
    Adv Neurol; 1990; 53():107-10. PubMed ID: 2146858
    [No Abstract]   [Full Text] [Related]  

  • 13. Mesolimbic dopaminergic neurones in the rotational model of nigrostriatal function.
    Kelly PH; Moore KE
    Nature; 1976 Oct; 263(5579):695-6. PubMed ID: 980114
    [No Abstract]   [Full Text] [Related]  

  • 14. Alterations in dopamine receptors: effect of lesion and haloperidol treatment.
    Goldstein M; Lew JY; Asano T; Ueta K
    Commun Psychopharmacol; 1980; 4(1):21-5. PubMed ID: 6105037
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence for NMDA/D2 receptor-receptor interactions in the rat striatum.
    Micheletti G; Lannes B; Warter JM; Zwiller J
    Adv Neurol; 1993; 60():128-32. PubMed ID: 8380517
    [No Abstract]   [Full Text] [Related]  

  • 16. Changes in guanine nucleotide sensitive and insensitive 3H-ADTN binding in striatum following substantia nigra lesions.
    Hirschhorn ID; Makman MH; Gardner EL
    Eur J Pharmacol; 1980 Mar; 62(1):123-4. PubMed ID: 6154585
    [No Abstract]   [Full Text] [Related]  

  • 17. On the cyclic nucleotides involvement in rat striatal function.
    Carenzi A; Govoni S; Spano PF; Trabucchi M
    Pharmacol Res Commun; 1976 Oct; 8(5):519-24. PubMed ID: 194261
    [No Abstract]   [Full Text] [Related]  

  • 18. [Neurophysiologic and pharmacologic evidence of autoregulationin the nigrostriatal system].
    Arushanian EB; Tolpyshev BA
    Biull Eksp Biol Med; 1981 Feb; 91(2):133-6. PubMed ID: 7194700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
    Seiler MP; Markstein R
    Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.